Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s176, 2023. DOI: 10.25251/skin.7.supp.176. Disponível em: https://skin.dermsquared.com/skin/article/view/2001. Acesso em: 19 apr. 2025.